ClinicalTrials.gg
CompletedNCT04330664Updated Apr 4, 2025

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

A Phase 1 interventional study of MRTX849 and TNO155 in Advanced Cancer, Metastatic Cancer and Malignant Neoplastic Disease, sponsored by Mirati Therapeutics Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Mirati Therapeutics Inc. (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2022, 4 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 1 of them phase 3. Neoplasm Metastasis · Bristol-Myers Squibb.

Enrollment
17th of 44
86 · median 66
Started
2020
with 3 others
Phase 1
16 of 50
none open now
Registered
35th of 50
by date

Among the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, this one is the 17th largest by enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2020, is one of 16 in phase 1, and was the 35th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.

Read the detailed description

This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally available small molecule inhibitor of KRAS G12C and TNO155 is a selective, orally bioavailable allosteric inhibitor of wild-type SHP2.

This study was terminated prior to phase 2 initiating. Only phase 1 of the study was conducted.

03

Conditions studied

  • Advanced Cancer
  • Metastatic Cancer
  • Malignant Neoplastic Disease

Keywords

  • KRAS G12C
  • Non-small cell lung cancer
  • Colorectal Cancer
  • Colon Cancer
  • Metastatic Cancer
  • Pancreatic Cancer
  • NSCLC
  • SHP2
  • Advanced Solid Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of a solid tumor with KRAS G12C mutation (phase 2 must be either Non-Small Cell Lung Cancer or Colorectal Cancer)
  • Unresectable or disease
  • No available treatment with curative intent
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
  • Other active cancer
  • Cardiac abnormalities
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Phase 1 Dose Exploration

    Dose escalation of TNO155 to determine maximum tolerated dose of TNO155 in combination with MRTX849

    Drug: MRTX849 · Drug: TNO155

  • Experimental
    Phase 1b Expansion

    Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with TNO155 to recommend Phase 2 regimens

    Drug: MRTX849 · Drug: TNO155

  • Experimental
    Phase 2

    Separate cohorts of patients stratified by histological diagnosis for evaluation of clinical activity to evaluate clinical activity of MRTX849 and TNO155 in combination

    Drug: MRTX849 · Drug: TNO155

Interventions

  • KRAS G12C Inhibitor

    Also known as: adagrasib

  • DrugTNO155

    SHP2 Inhibitor

06

What researchers measure

Primary outcomes

  1. Characterize the safety of MRTX849 and TNO155 in patients having advanced solid tumor malignancies with KRAS G12C mutation.

    Number of participants with treatment related adverse events

    Time frame: 20 months

  2. Evaluate the pharmacokinetics of MRTX849 and TNO155

    Blood plasma concentration

    Time frame: 20 months

Secondary outcomes

  1. Establish maximum tolerated dose

    Number of participants with dose limiting toxicity

    Time frame: 12 months

  2. Evaluate clinical activity of MRTX849

    Objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)

    Time frame: 20 months

07

Study locations

17 sites
  • Local Institution - 002-805
    Los Angeles, California 90095, United States
  • Local Institution - 002-803
    Orange, California 92868, United States
  • Local Institution - 002-828
    Chicago, Illinois 60611, United States
  • Local Institution - 002-942
    Wichita, Kansas 67214, United States
  • Local Institution - 002-804
    Boston, Massachusetts 02114, United States
  • Local Institution - 002-808
    Boston, Massachusetts 02215, United States
  • Local Institution - 002-811
    Novi, Michigan 48377, United States
  • Local Institution - 002-809 B
    Creve Coeur, Missouri 63141, United States
  • Local Institution - 002-809 A
    Saint Louis, Missouri 63110, United States
  • Local Institution - 002-809 C
    Saint Louis, Missouri 63129, United States
  • Local Institution - 002-809
    Saint Louis, Missouri 63130, United States
  • Local Institution - 002-809 E
    Saint Louis, Missouri 63136, United States
  • Local Institution - 002-809 D
    Saint Peters, Missouri 63376, United States
  • Local Institution - 002-813
    New York, New York 10016, United States
  • Local Institution - 002-806
    New York, New York 10065, United States
  • Local Institution - 002-801
    San Antonio, Texas 78229, United States
  • Local Institution - 002-810
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Jul 2022, 27 months.

Of 286 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 27 months is below that.

Counting every sponsor, half of 496 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2020
First posted
Apr 1, 2020
StartActual
Apr 7, 2020
Primary completionActual
Jul 29, 2022
CompletionActual
Feb 24, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04330664
Collaborators
Novartis
Responsible party
Sponsor
First posted
Apr 1, 2020
Start date
Apr 7, 2020
Primary completion
Jul 29, 2022
Completion
Feb 24, 2025
Last update
Apr 4, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adagrasib · Batoprotafib

Start the discussion